Comparing the current results to its competitors, Amneal Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 9.93 % year on year. The sales growth was above Amneal Pharmaceuticals Inc 's competitors' average revenue growth of 4.58 %, achieved in the same quarter.
Amneal Pharmaceuticals Inc Net Income in the 2 quarter 2026 grew year on year by 95.49%, while most of its competitors have experienced a contraction in net income by -92.33 %.
Amneal Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The competitive landscape is affected by the timing of new product introductions, which significantly influence financial results. Entry of additional competitors typically reduces the volume and pricing of impacted products. Pricing is also affected by external factors beyond the company's control. The Affordable Medicines segment generates revenues from both U.S. and international markets and includes 61 products with pending Abbreviated New Drug Applications (ANDAs) and 43 products in development, primarily non-oral solid products.
With revenue growth of 9.93 % within Overall company, Amneal Pharmaceuticals Inc achieved improvement in market share, within Overall company to approximately 2.63 %. << More on AMRX Market Share.
*Market share is calculated based on total revenue.
August 8, 2024
In a significant advancement for Parkinson’s disease (PD) management, Amneal Pharmaceuticals, Inc. has received U.S. Food and Drug Administration (FDA) approval for CREXONT, an innovative formulation of carbidopa and levodopa (CD/LD). The introduction of CREXONT as an extended-release capsule is anticipated to provide enhanced therapeutic options for PD patients. Furthermore, the company has reported impressive financial growth, surpassing its competitors in revenue generation for the first quarter of 2024. This article aims to explore the implications of CREXONT s approval on the pharmaceutical landscape for PD treatment, alongside an analysis of Amneal’s market performance. Parkinson’s disease is a ...
August 7, 2024
Recent Advances in Parkinson s Disease Treatment and Injectable Medications: A Spotlight on Amneal Pharmaceuticals Amneal Pharmaceuticals has garnered attention recently for its notable developments in the pharmaceutical landscape, particularly with its advancements in treatments for neurological disorders and other medical needs. This article provides an overview of the U.S. Food and Drug Administration (FDA) approvals for two significant products by Amneal: CREXONT, an innovative treatment for Parkinson s disease, and a new injectable formulation of potassium phosphates, alongside FOCINVEZ, a ready-to-use version of fosaprepitant. Parkinson s disease (PD) is a progressive neurological disorder that ...
July 30, 2024
The pharmaceutical landscape is continuously evolving, with companies striving to enhance drug delivery systems and patient outcomes. Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, has recently marked significant milestones in the field of injectable medications. This article reviews Amneal s recent FDA approvals for potassium phosphates injection and the launch of FOCINVEZ an innovative ready-to-use version of fosaprepitant. Furthermore, Amneal is expanding its biosimilars portfolio with the introduction of omalizumab, a crucial medication for managing allergic conditions. Together, these developments underscore Amneal s commitment to improving clinical efficiencies ...
July 10, 2024
Amneal Pharmaceuticals, a prominent player in the pharmaceutical industry, has recently made significant advancements in their portfolio with the launch of FOCINVEZ, a ready-to-use injectable, and the addition of six new therapies to their injectables portfolio. These developments highlight Amneal s commitment to innovation and addressing critical healthcare needs. Additionally, the company has released their 2023 Environmental, Social, and Governance (ESG) Report, showcasing their progress in sustainable practices, human capital management, and philanthropic partnerships. In this article, we will delve into the details of these achievements and their implications for Amneal Pharmaceuticals.Amneal Introduces...
July 1, 2024
Amneal Pharmaceuticals Ramps Up Biosimilars and Injectables Portfolios to Address Critical ShortagesBridgewater, N.J. - In a strategic move to address critical shortages and cater to the growing demand for quality healthcare solutions, Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) has announced the expansion of both its biosimilars and injectables portfolios.The addition of omalizumab, referencing XOLAIR, marks a significant milestone for Amneal in bolstering its biosimilars pipeline. Omalizumab is a humanized monoclonal antibody designed to target free immunoglobulin E (IgE). This injectable prescription drug is widely prescribed for the treatment of chronic conditions such as severe persistent allergic asthm...
June 5, 2024
Amneal Pharmaceuticals Bolsters Injectables Portfolio with Six New Therapies, Surpassing 40 Products for U.S. MarketAmneal Pharmaceuticals, Inc. (Nasdaq: AMRX) has recently demonstrated impressive growth with the addition of six new injectable products to its expanding portfolio during the second quarter of 2024. The company now offers over 40 commercial injectables for the U.S. institutional market, aiming to address shortages of critical medical treatments. Amneal s achievement of revenue increase by 18.28% year on year in the first quarter of 2024 is notably higher than the average revenue growth of 6.18% observed among its competitors in the same period, highlighting its strong market performance.The sig...
Publicly Traded Peers of Amneal Pharmaceuticals Inc
Viatris Inc Share Performance
+0.61%
Over The Past 5 Days
Viatris Inc
Profile
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Coresite Realty Corp operates as a real estate investment trust (REIT) that specializes in the ownership, acquisition, and development of data centers. The company's business model revolves around providing secure and reliable colocation and interconnection solutions for customers' mission-critical IT infrastructure. By offering robust infrastructure and high-quality services, Coresite aims to foster long-term relationships with its diverse customer base, comprised of enterprises, telecommunications carriers, cloud providers, and content and media firms.
Collegium Pharmaceutical Inc's business model revolves around the development and commercialization of innovative products specifically designed to address the limitations of existing treatment options in pain management. They focus on developing extended-release formulations that offer abuse-deterrent properties to enhance patient safety and combat prescription drug abuse. By leveraging strategic partnerships, they aim to bring their products to market efficiently and effectively.
Coherus Biosciences Inc is a biopharmaceutical company focused on developing and commercializing high-quality biosimilar therapeutics. Their business model revolves around leveraging their expertise in cell culture, protein purification, formulation development, and analytical methods to manufacture and market biosimilar products. By providing cost-effective alternatives to expensive biologic drugs, Coherus Biosciences aims to make healthcare more accessible and affordable for patients.
Cardinal Health Inc operates as a prominent integrated healthcare services provider in the United States, specializing in the distribution of pharmaceuticals and medical products to various healthcare settings, including retail pharmacies and hospitals. The company enhances healthcare efficiency through a range of services such as inventory management, medication therapy management, and data analytics solutions aimed at optimizing operations and improving patient care.
Sources:
Amneal Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Amneal Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
